@article{GeigerKoenigOberwinkleretal.2022,
  author    = {Geiger, Nina and K{\"o}nig, Eva-Maria and Oberwinkler, Heike and Roll, Valeria and Diesendorf, Viktoria and F{\"a}hr, Sofie and Obernolte, Helena and Sewald, Katherina and Wronski, Sabine and Steinke, Maria and Bodem, Jochen},
  title     = {Acetylsalicylic acid and salicylic acid inhibit SARS-CoV-2 replication in precision-cut lung slices},
  series = {Vaccines},
  volume    = {10},
  journal   = {Vaccines},
  number    = {10},
  issn      = {2076-393X},
  doi       = {10.3390/vaccines10101619},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-289885},
  year      = {2022},
  abstract  = {Aspirin, with its active compound acetylsalicylic acid (ASA), shows antiviral activity against rhino- and influenza viruses at high concentrations. We sought to investigate whether ASA and its metabolite salicylic acid (SA) inhibit SARS-CoV-2 since it might use similar pathways to influenza viruses. The compound-treated cells were infected with SARS-CoV-2. Viral replication was analysed by RTqPCR. The compounds suppressed SARS-CoV-2 replication in cell culture cells and a patient-near replication system using human precision-cut lung slices by two orders of magnitude. While the compounds did not interfere with viral entry, it led to lower viral RNA expression after 24 h, indicating that post-entry pathways were inhibited by the compounds.},
  language  = {en}
}